| Nov 13 |
Orgenesis GAAP EPS of $1.93, revenue of $0.3M
|
| Nov 13 |
Orgenesis Provides Third Quarter 2024 Business Update
|
| Oct 21 |
Orgenesis Commences Trading on OTCQX® Best Market
|
| Sep 24 |
Why Maison Solutions Shares Are Trading Higher By Around 91%; Here Are 20 Stocks Moving Premarket
|
| Sep 23 |
Orgenesis announces 1-for-10 reverse stock split to regain Nasdaq compliance
|
| Sep 23 |
Orgenesis Announces Reverse Stock Split
|
| Aug 29 |
Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia
|
| Aug 14 |
Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally
|
| Aug 9 |
Orgenesis GAAP EPS of $0.23
|
| Aug 8 |
Orgenesis Provides Second Quarter 2024 Business Update
|
